ReviewEuropean urology focus2025
Defining the Role of Surgical Resection in Metastatic Renal Cell Carcinoma: A Mini Review.
Review in European urology focus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Ongoing advances in systemic therapy for metastatic renal cell carcinoma (mRCC) have left the role of surgical resection in this setting uncertain. In this mini review, we examine historical data and ongoing clinical trials evaluating the role of cytoreductive nephrectomy and metastasectomy in mRCC. We note that patients undergoing upfront nephrectomy may have a delayed opportunity to receive systemic therapy, which poses a significant risk, particularly for individuals with poor-risk or actively progressing disease. Although patients undergoing resection after response to systemic therapy have favorable outcomes, ongoing randomized trials will provide clarity regarding the role of deferred nephrectomy and metastasectomy in the context of current systemic regimens. PATIENT SUMMARY: In this mini review, we assess data on surgery to remove the primary tumor and its metastatic sites in kidney cancer. Drug options for metastatic kidney cancer have greatly improved, so there is a need to evaluate how surgery is used for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.